Milea Timbergen

180 37 . Kim Y, Rosario MS, Cho HS, Han I. Factors Associated with Disease Stabilization of Desmoid-Type Fibromatosis. Clin Orthop Surg. 2020;12(1):113-119. 38 . Turner B, Alghamdi M, Henning JW, Kurien E, Morris D, Bouchard-Fortier A, et al. Surgical excision versus observation as initial management of desmoid tumors: A population based study. Eur J Surg Oncol. 2019;45(5):699-703. 39 . Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017;28(10):2399-2408. 40 . Eastley N, Hennig IM, Esler CP, Ashford RU. Nationwide trends in the current management of desmoid (aggressive) fibromatosis. European Journal of Surgical Oncology. 2014;40(11):S47. 41 . Quast DR, Schneider R, Burdzik E, Hoppe S, Moslein G. Long-term outcome of sporadic and FAP- associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients. Fam Cancer. 2016;15(1):31-40. 42 . Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, et al. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018;379(25):2417-2428. 43 . Reitamo JJ, Hayry P, Nykyri E, Saxen E. The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982;77(6):665-673. 6